Oryzon announces appointment of new Chief Medical Officer and expansion of its Medical Department

BARCELONA, SPAIN and CAMBRIDGE MA.

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that Roger Bullock, MD, has been appointed Chief Medical Officer (CMO). This appointment strengthens the company's epigenetic leadership with a veteran of neurological and psychiatric disorders who brings extensive clinical and medical experience in the field of Alzheimer’s disease, Huntington’s disease and other neurodegenerative disorders.

Click here to see the full Press Release